Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $2.3 Million Public Offering of Common Stock of Sigma Labs, Inc. - August 3, 2019
- Sichenzia Ross Ference LLP Ranked as a Top Issuer Counsel for 2019 Q2 - July 24, 2019
- Sichenzia Ross Ference LLP Represents ThinkEquity in $1.35 Million Underwritten Public Offering of ADSs of Immuron Limited - July 23, 2019